title: Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire.
abstract: OBJECTIVE
  The aim of this study was to validate the ability of symptom frequency questionnaire to differentiate between irritable bowel syndrome (IBS) patients and healthy subjects.
  
  
  BACKGROUND
  A digestive symptom frequency questionnaire (DSFQ) was previously used in a food efficacy trial in a non-IBS population with mild gastrointestinal symptoms.
  
  
  METHODS
  We compared 2 well-defined populations: 100 IBS patients fulfilling Rome III criteria (mean age 32 y; range, 18 to 59 y), and 100 sex-matched and age-matched healthy subjects. Frequency of individual digestive symptoms (abdominal pain/discomfort, bloating, flatulence, borborygmi) was assessed using a 5-point Likert scale (from none to everyday of the week) and the IBS severity with the IBS-SSS questionnaire. Health-Related Quality of life (HRQoL) was assessed with the Food and Benefits Assessment (FBA) and Functional Digestive Disorders Quality of Life (FDDQL) questionnaires. The digestive (dis)comfort dimension of these questionnaires was considered as the main dimension for HRQoL.
  
  
  RESULTS
  The DSFQ discriminated IBS from healthy subjects with a significant difference (P<0.001) between groups (estimated mean difference=5.58; 95% CI, 4.91-6.28). On the basis of the ROC curve (AUC=0.9479), a cutoff value of 5 gives a sensitivity of 92% and a specificity of 84%, with a positive likelihood ratio of 5.75. Composite score of symptoms correlated strongly (P<0.0001) with digestive discomfort measured by FDDQL (-0.816), digestive comfort measured by FBA (-0.789), and the IBS-SSS score (0.762).
  
  
  CONCLUSIONS
  Measurement of digestive symptom frequency by means of the DSFQ can differentiate IBS from healthy subjects, and shows a good correlation with other validated questionnaires (clinical trial #NCT01457378).
authors.affiliation: *Digestive System Research Unit, University Hospital Vall d'Hebron, CIBEREHD †Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain ‡Danone Research, Palaiseau §Eurofins Optimed, Gières ∥Biorfortis, Nantes, France.
authors.forename: Fernando
authors.initials: F
authors.lastname: Azpiroz
authors.forename: Denis
authors.initials: D
authors.lastname: Guyonnet
authors.forename: Yves
authors.initials: Y
authors.lastname: Donazzolo
authors.forename: David
authors.initials: D
authors.lastname: Gendre
authors.forename: Jérôme
authors.initials: J
authors.lastname: Tanguy
authors.forename: Francisco
authors.initials: F
authors.lastname: Guarner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005602:France; D064368:Healthy Volunteers; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis* / Q000523:psychology; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires / Q000592:standards*; D063189:Symptom Assessment / Q000379:methods* / Q000592:standards; D055815:Young Adult